BMS Reports Results of Triple Regimen in P-III ELOQUENT-1 Study for Patients with Newly Diagnosed Untreated Multiple Myeloma

 BMS Reports Results of Triple Regimen in P-III ELOQUENT-1 Study for Patients with Newly Diagnosed Untreated Multiple Myeloma

BMS Reports Results of Triple Regimen in P-III ELOQUENT-1 Study for Patients with Newly Diagnosed Untreated Multiple Myeloma

Shots:

  • The P-III ELOQUENT-1 study involves assessing of Empliciti (elotuzumab)+ Revlimid (lenalidomide) and dexamethasone (ERd) vs Rd in transplant-ineligible patients with newly diagnosed, previously untreated MM
  • The P-III ELOQUENT-1 study resulted in not meeting its 1EPs of PFS while the safety profile of ERd is consistent with its known profiles
  • Empliciti is an immunostimulatory Ab targeting SLAMF7 and has received the FDA’s approval in 2015 as a combination therapy with Rd for MM patients prior treated with one to three therapies and in 2018 approved as EPd combination therapy for MM patients prior treated with two therapies

Click here ­to­ read full press release/ article | Ref: BMS | Image: Under Consideration

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post